Philipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, Deborah A Forst, Elizabeth Gerstner, Justin T Jordan, Ina Ly, Scott R Plotkin, Nancy Wang, Maria Martinez-Lage, Sebastian F Winter, Joerg-Christian Tonn, Kai Rejeski, Louisa von Baumgarten, Daniel P Cahill, Brian V Nahed, Ganesh M Shankar, Jeremy S Abramson, Jeffrey A Barnes, Areej El-Jawahri, Ephraim P Hochberg, P Connor Johnson, Jacob D Soumerai, Ronald W Takvorian, Yi-Bin Chen, Matthew J Frigault, Jorg Dietrich
BACKGROUND: Chimeric antigen receptor (CAR) T-cells targeting CD19 have been established as a leading engineered T-cell therapy for B-cell lymphomas; however, data for patients with central nervous system (CNS) involvement are limited. METHODS: We retrospectively report on CNS-specific toxicities, management, and CNS response of 45 consecutive CAR T-cell transfusions for patients with active CNS lymphoma at the Massachusetts General Hospital over a five-year period...
July 4, 2023: Neuro-oncology